Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by ...

For years, Roche has been increasing medicine production in the United States. That could pay off for the drug maker as ...

The United States has a $115.5 billion trade deficit in pharmaceutical products, which the Trump administration has suggested ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

A recent report has revealed some concerning news for U.S. consumers: a 25% tariff on imported pharmaceutical products could ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

The report, not made public, was commissioned by the main US pharmaceutical lobby, the Pharmaceutical Research and ...

Apollo chief economist Torsten Sløk predicted “empty shelves” in the next few weeks as a result of tariff-induced supply ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.